Penpulimab - Akeso Biopharma/Chia Tai Tianqing Pharmaceutical Group
Alternative Names: AK 105 - Akeso Biopharma/Chia Tai Tianqing Pharmaceutical Group; AnnikoLatest Information Update: 13 Jul 2024
At a glance
- Originator Akeso Biopharma
- Developer Akeso Biopharma; Beijing Cancer Hospital; Chia Tai Tianqing Pharmaceutical Group; Fudan University
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hodgkin's disease; Nasopharyngeal cancer; Non-small cell lung cancer
- Phase III Liver cancer
- Phase II Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Glioblastoma; Head and neck cancer; Neuroendocrine tumours; Pancreatic cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer; Thyroid cancer; Urogenital cancer
- Phase I/II Mesothelioma; Oesophageal cancer; Thymoma; Uterine cancer
Most Recent Events
- 31 May 2024 Updated efficacy and adverse events data from a phase II trial in Nasopharyngeal cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 01 May 2024 The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School and Chia Tai Tianqing Pharmaceutical completes a phase-II clinical trial in Pancreatic cancer (Combination therapy, Late-stage disease, Metastatic disease, First-line therapy) in China (IV) (NCT05493995)
- 23 Jan 2024 Phase-I/II clinical trials in Cholangiocarcinoma (Combination therapy) (IV) before January 2024 (Akeso Biopharma pipeline, January 2024)